Drug Profile
Research programme: anti-cancer therapeutics - Daiichi Sankyo Company/Max Planck Innovation/The Lead Discovery Center
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Max Planck Innovation; The Lead Discovery Center
- Class Antineoplastics
- Mechanism of Action Cell proliferation inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in Germany
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in Japan
- 11 Jul 2017 Daiichi Sankyo Company, Max Planck Innovation and the Lead Discovery Center agree to co-develop anti-cancer therapeutics